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Thursday, March 7
10:30 - 11:30  Studio 2013 
organised by Siemens Healthcare 
SY 1 
Advanced multimodality breast image reading 
Moderator: 
T. Hartley; Erlangen/DE 
Place of digital breast tomosynthesis in diagnostic investigation of 
breast lesions: old and new paradigms 
C. Van Ongeval, A. Van Steen, S. Postema, J. Soens; Leuven/BE 
Digital mammography (DM) has proven to be equal or better than film-screen mam-
mography (FSM), in a diagnostic and screening environment. The introduction of DM 
had no impact on the diagnostic work-up of breast lesions but improved the digital 
exchange of information. Digital data can be used for new techniques. One of these 
techniques is digital breast tomography (DBT). In DBT an acquisition sequence 
of 10 to 25 projection images is obtained from a limited range of angulations of 
the X-ray tube with the breast in a constant position. DBT overcomes one of the 
main limitations of 2D in which lesions were miss-diagnosed due to overlapping 
tissue. Recent studies report not only a better detection of stellant lesions but 
also a better characterisation of breast masses. Most studies were performed in 
a diagnostic environment. Studies on the role of DBT in screening are ongoing. 
DBT will have an impact on the workflow: for BIRADS 3 lesions DBT can result 
in a better classification of the abnormality, in some cases additional ultrasound 
can thus be avoided. For BIRADS 5 lesions, a better definition of the tumour and 
multifocality of the disease can be realized. It is unclear whether in the standard 
investigation of dense breast and patients with positive family history DBT (one/
two-view) in addition to 2D is necessary. The relation between DBT and magnetic 
resonance imaging is also unclear. More research on the place of DBT in all steps 
of the diagnosis is essential for this promising new technique. 
Learning Objectives:
1. To appreciate the advantages and disadvantages of the different imaging 
methods in breast cancer diagnosis.
2. To learn about strengths and weaknesses of digital breast tomosynthesis in 
the diagnosis of breast lesions.
3. To understand the impact of digital breast tomosynthesis on the diagnostic 
work out of breast lesions.
Place of breast MRI in diagnostic investigation of breast lesions 
E. Wenkel; Erlangen/DE 
The classical and most wide-spread breast imaging modalities comprise mammog-
raphy and sonography. MRI as a high sensitive tool for cancer detection is often not 
so easily available for women due to different reasons like reimbursements from 
health insurances or lack of scanners. More recent developments like tomosynthesis 
claim to replace conventional mammography. Hence each modality is not suitable 
for every patient or maybe not every patient needs all available imaging modali-
ties. On the basis of clinical examples we want to discuss the different imaging 
methods dependent on the patient’s clinical history, breast density and histology. 
Learning Objectives:
1. To discuss different approaches to detect breast cancer.
2. To learn criteria to distinguish between benign and malignant breast lesions.
3. To discuss the different imaging modalities for different patients.
Panel discussion 
12:30 - 13:30  Room G/H 
organised by SuperSonic Imagine
SY 2 
The benefits UltraFastTM imaging brings to 
ultrasound 
Moderator: 
J. Souquet; Aix-en-Provence/FR 
Advantages and limitations of ShearWaveTM elastography for 
imaging prostate cancer and guiding biopsy 
P.S. Zoumpoulis; Athens/GR 
Benefits of UltraFastTM Doppler in the clinical workflow 
G. Ivanac; Zagreb/HR 
Experiences with the Aixplorer and ShearWaveTM elastography for 
the staging of liver fibroses 
V. Vilgrain; Clichy/FR 
Advances in breast imaging with ShearWaveTM elastography 
F.K.W. Schäfer; Kiel/DE 
12:30 - 13:30  Room I/K 
organised by Bayer HealthCare
SY 3 
New insight in breast cancer imaging 
Moderator: 
J. Camps Herrero; Valencia/ES 
Breast MRI for screening breast cancer, why, who and when? 
L. Umutlu; Essen/DE 
Overtreatment due to breast MRI - a threat, a myth, or both? 
C.K. Kuhl; Aachen/DE 
MIPA study: study design, goals and rollout 
F. Sardanelli; Milan/IT 
12:00 - 13:30  Studio 2013 
organised by Siemens Healthcare
SY 4 
Challenges in breast imaging 
Moderator:
J. Barkhausen; Lübeck/DE 
3D automated breast ultrasound: accuracy and diagnostic potentials 
M.J.C.M. Rutten; ‘s-Hertogenbosch/NL 
Automated 3D breast ultrasound is a new technique, which scans the breast auto-
matically and almost entirely. Data sets can be stored and are available for 3D cross 
correlating review. This new technique eliminates the subjectivity of conventional 
ultrasound, and disconnects the acquisition and assessment of US data. It facili-
tates the possibility of double reading, the presurgical workup planning, review of 
follow-up studies and the application of computer aided detection. Diagnostic yield, 
sensitivity, specificity, positive and negative predictive values will be presented, as 
well as the interobserver agreement. 3D US appears to be a reliable imaging tech-
nique for the detection and classification of benign and malignant breast tumours. 
Patient experiences less discomfort in comparison with MRI and mammography. 
Automated 3D ultrasound can be implemented in the clinical radiological setting 
and possibly in a personalised screening program for breast cancer. 
Learning Objectives:
1. To become familiar with the 3D breast ultrasound technique and scanning 
protocols.
2. To comprehend the indications and limitations of 3D breast ultrasound.
3. To become familiar with the diagnostic accuracy of 3D breast ultrasound and 
to appreciate the potential added value for breast cancer screening.
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High image quality with lower dose mammography 
D. Uhlenbrock; Dortmund/DE 
The talk deals with a study to investigate dose saving and image quality of digital 
mammography acquired without anti-scatter grid in combination with a novel 
software-based scatter correction (SBSC). The SBSC for grid-less acquisition 
was initially validated by numerical simulations and physical phantom studies. 
Patient dose may be reduced by grid-less acquisition (no grid attenuation of pri-
mary radiation) and optimised breast-thickness-(BT)-dependent dose reduction 
factors (DRF) were determined from these measurements. For clinical evaluation, 
a feature analysis study with 75 patients having known mammographic findings 
was conducted. Each patient underwent two mammography exams during one 
compression phase: 1. with grid; 2. without grid, with SBSC. The tube current-time 
product of the second acquisition was reduced according to the DRF, all other 
imaging parameters were fixed. For each case, comparison of both mammograms 
with respect to general image quality was performed by 5 blinded readers using 
a 7-point Likert scale. Dose saving is highest for smaller breasts. The DRF in the 
clinical study ranged from 33% to 15%. Weighted with the BT-distribution of a typi-
cal screening population, the average dose reduction is 23%. The average of the 
general mammographic image quality comparing the two acquisitions was less than 
0.3 points on the Likert-scale with a 95% confidence level. Based on these results, 
the grid-less acquisition with SBSC was rated to be of equivalent image quality 
as the acquisition with grid. Conclusion: Grid removal in combination with SBSC 
may reduce patient dose in digital mammography while maintaining image quality. 
Breast imaging from a pathologist’s perspective 
A. Hartmann; Erlangen/DE 
The interdisciplinary tumour conference, where breast surgical oncologists, medical 
oncologists and pathologists discuss the diagnosis and treatment of breast cancer 
patients is crucial in modern breast cancer centers. Especially a close collaboration 
between the diagnosing radiologist and the pathologist is very important. 1. The 
exact description of the radiologic findings (preferable with electronic images) has to 
be provided to the pathologist who is diagnosing breast cancers in needle biopsies. 
The grade of suspicion for malignancy will guide the pathologist in the workup of 
these biopsies. Specific tumour types (e.g. hereditary breast cancer in patients 
with BRCA-1-Mutations) have both specific radiologic and pathologic features. 2. 
In the workup of surgical specimens with microcalcifications the exact location and 
amount of the microcalcification has to be provided to the pathologist. In crucial 
cases the paraffin blocks can be investigated for the presence of minute areas of 
microcalcification to correlate the pathological to the radiological findings. 3. Fine 
needle aspiration cytology can be regarded as a very useful method to investigate 
suspicious lymph nodes, for instance in patients who would be candidates for 
neoadjuvant therapy. Histological typing of breast cancer and investigation of the 
hormone receptor and Her2 expression is possible in these specimens using the 
cytoblock technology. 
MR breast in clinical routine 
W.A. Kaiser; Jena/DE 
MR-mammography or breast MRI is in clinical use since 30 years. Despite the long 
childhood it is still considered as “sophisticated”, “complicated”, “unspecific” etc. 
The mantra “MRI has as high sensitivity but a low specificity” is obviously living 
forever. On the other hand it is a wonderful technique if all factors come together. 
A lot of technical details have to be considered. Information from patient’s history is 
extremely important and a lot of very helpful morphological and kinetic signs have 
to be used in order to find a high sensitivity and specificity as well. This can be per-
formed nowadays. The lecture will describe the specific features to reach this goal. 
Panel discussion
14:00 - 15:30  Studio 2013 
organised by Siemens Healthcare
SY 5 
Chances with digital breast tomosynthesis (DBT) 
Moderator: 
T.H. Helbich; Vienna/AT 
Physical challenges with digital breast tomosynthesis 
H. Bosmans; Leuven/BE 
Introduction: Digital breast tomosynthesis (DBT) is a new modality that aims for 3D 
visualisation of the breast tissue. The technique can be realised following different 
choices of geometry, exposure settings and image reconstruction algorithms. The 
same mammography system may provide a combined 2D or 2D like image along 
with tomosynthesis. The clinical potential of this new modality is substantial and topic 
of several on-going clinical trials. In this presentation, we will address the technical 
parameters with potential impact on clinical performance. Methods: The technical 
performance of DBT will be explained from investigations performed on the Siemens 
Mammomat Inspiration system with tomosynthesis functionality. This system uses a 
50° angle and 25 projections. We will focus in particular on the 3D aspects of DBT, 
such as spatial resolution in all 3 directions and the efficiency of suppressing the 
background structure in the reconstructed planes. Several new phantoms have been 
explored for this purpose. Selected test methods allow performance comparison 
between 2D mammography and DBT. Conclusion: When using test objects that 
mimick a mammographic background, comparative technical evaluations of 2D 
mammography and DBT confirm the better performance of DBT. In practice, both 
technical and practical considerations may guide the implementation of DBT as 
standalone or complementary modality to 2D mammography. 
Learning Objectives:
1. To compare technical aspects of 2D digital mammography to DBT.
2. To explore test methods for the 3D aspects of DBT.
3. To discuss the combined use of 2D and DBT in terms of data volume and 
reading.
Experiences with digital breast tomosynthesis in screening 
S. Zackrisson; Malmö/SE 
Mammography is not the ultimate method for screening - between 15 and 30% of 
all cancers are missed at mammography screening and detection is particularly 
difficult in dense breasts. There are several reasons for the non-detection of tu-
mours; the normal anatomy being the major one. Digital breast tomosynthesis, 
DBT is a three-dimensional radiographic technique which, to a great extent, may 
overcome the problem with overlapping tissues in breast cancer detection. The 
presentation will focus on our initial experiences of DBT within the Malmö Breast 
Tomosynthesis Screening Trial. 
Learning Objectives:
1. To understand the potential impact of DBT on sensitivity and specificity of 
breast cancer detection in screening.
2. To appreciate the limitations of DBT in screening.
3. To understand the impact of DBT on image interpretation time and work-flow 
in screening.
Value of tomosynthesis for the assessment of screen-detected 
abnormalities 
S.H. Heywang-Köbrunner1, T. Mertelmeier2, S. Sedlacek1, S. Wulz-Horber1; 
1Munich/DE, 2Erlangen/DE 
Purpose: A study had been performed to countercheck whether tomosynthesis 
(TS) performed in one projection can replace all or part of the additional views 
(AV) that are used to assess mammographically detected lesions. The hypothesis 
is that tomosynthesis is at least equivalent to conventional assessment by AV.
Methods and Materials: Inclusion criteria: any assessment requiring at least one 
additional mammographic view and assessments that require further histopathologi-
cal assessment are consecutively invited to obtain an additional tomosynthesis. 
In all cases TS is always performed in addition to the indicated AVs. The study is 
approved by the local Ethics Committee and by the Bureau of Radiation Protec-
tion. All invited screenees sign informed consent. Equipment: Siemens Inspiration
Results: The study, for which 300 women have been included, has just been 
concluded. Evaluation is still ongoing. The results of all included patients will be 
presented. Our last evaluation was based evaluation of 262 lesions in 246 patients. 
Results have been verified by histology or 6-24 months follow-up. So far sensitivity 
was slightly better for TS+AVs than for TS than for AVs (trend), while specificity 
was significantly better for TS than for TS+AV than AV. Advantages of TS were 
seen any breast density, mostly in breast density ACR2 and 3. >92% of AVs were 
restrospectively considered unnecessary.
Discussion: TS is appears to be a valuable additional method for assessing 
indeterminate lesions. 
Clinical experiences with digital breast tomosynthesis in follow up 
diagnostics 
F. Taşkın; Aydin/TR 
We use digital breast tomosynthesis (DBT) in our department during last 18 
months. In our clinical practice, we perform MLO position DBT after two standard 
positions (CC and MLO) digital mammography (DM) in women with dense breast. 
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After mammography, we perform whole breast sonography. We performed 3024 
DM and DBT examinations (1707 patients were referred for diagnostic, remaining 
1317 were screening purposes). Seven-hundred sixteen lesions were categorised 
as BI-RADS 3, 391 were categorised as BI-RADS 4, and 228 were categorised as 
BI-RADS 5. On DM, 14% of malignant lesions were not visible, whereas visible on 
DBT. Thirty-five percent of malignant lesions were better visible with DBT than DM. 
In 43% of lesions, DM and DBT were equal for lesion detection and description. 
Twenty -seven lesions (8%) were not visible both in DM and DBT. Comparing the 
DM to DBT for BI-RADS categorisation; final decision was changed with DBT in 
21% of all malignant cases. Histopathologically proven 41 benign and 57 malignant 
microcalcifications were visible on DM and DBT. In 97% of cases both DM and DBT 
were equal for visibility of microcalcifications. DBT seems less efficient than DM for 
evaluation of scattered microcalcifications with relatively low density. DBT is also 
helpful for determine spatial distribution of microcalcifications. Diagnostic imaging 
centers like our department can use DBT together with DM as a supplementary 
technique. In our limited clinical experience, using DM and DBT together improves 
the mammographic performance. 
Learning Objectives:
1. To share our clinical experiences about using digital breast tomosynthesis.
2. To explain benefits and limitations of using digital breast tomosynthesis as a 
supplementary examination.
The future of breast tomosynthesis 
T.H. Helbich; Vienna/AT 
Breast cancer remains a major cause of cancer death among women world wide. 
Mammography is an accepted screening modality. However, accuracy of mam-
mography is reduced by several factors. Among those breast density seems to play 
a major role. Thus up to 15-30% of carcinomas are not depicted by mammography 
due to superposition and poor contrast. The elimination of superposition of cancer 
by tomosynthesis as well as the improvement of contrast by contrast enhanced 
tomosynthesis seems to have a major impact in the future development of mam-
mography systems. These systems will offer tomosynthesis as well as contrast 
enhanced techniques. In this talk we will present the first results of a prototype 
which allows contrast enhanced tomosynthesis in the detection and characterisa-
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Conventional ultrasonography is often the first diagnostic step in the evaluation of 
the pancreas. The introduction of contrast-enhanced ultrasonography (CEUS) has 
led to great developments in the diagnostic capabilities of ultrasound. The greater 
accuracy of CEUS compared to baseline US can immediately result in better 
diagnostic workup and treatment planning. The immediate use of CEUS in the 
work up of a pancreatic lesion detected by means of ultrasound may be therefore 
proposed to save time (faster diagnosis) and money (move directly to MRI for cystic 
tumours). Acoustic Radiation Force Impulse imaging (ARFI) is a new technique able 
to provide numerical measurements of the tissue stiffness, improving the tissue 
characterisation. Virtual Touch quantification is a quantitative implementation of 
ARFI technology, which provides numerical measurements (shear wave velocity 
values, measured in meters per second) of the tissue stiffness: the stiffer a tissue 
is, the greater the shear wave speed will be. Virtual Touch tissue quantification can 
be also applied in the analysis of fluids and is potentially able to differentiate more 
complex (mucinous) from simple (serous) content in studying pancreatic cystic 
lesions. Attendees of this symposium will learn how CEUS and ARFI Shear Wave 
imaging can help them better understand and differentiate pancreatic pathology. 
Friday, March 8
12:30 - 13:30  Room D1 
organised by Bayer HealthCare
SY 6 
Programme to be announced
12:30 - 13:30  Room G/H 
organised by Bracco
SY 7 
Programme not available by date of print 
12:30 - 13:30  Room I/K 
organised by GE Healthcare
SY 8 
Evidence of avant-garde MR 
Moderator: 
D. Pickuth; Saarbrücken/DE 
Sharing GE MR vision and future 
R. Hausmann; Waukesha, WI/US 
Getting closer to metallic implants 
M. Padrón; Madrid/ES 
Streamlining workflow through integrated reviewing and post-processing 
C. Dromain; Villejuif/FR 
12:30 - 13:30  Room L/M 
organised by Siemens Healthcare
SY 9 
Pioneering futures in ultrasound 
Moderator: 
P.S. Sidhu; London/UK 
Strain imaging in the breast - with a focus on the new VTIQ technology 
C.S. Balleyguier; Villejuif/FR 
Breast elasticity imaging is a complementary functional imaging tool in breast 
ultrasound. Breast elasticity can help to characterise benign and malignant breast 
lesions, especially for non typically benign or malignant breast lesions, such as 
BIRADS 3 or 4a. New developments are focused on shear wave elasticity imaging, 
less dependent on individual sonographer technique. Attendees of this symposium 
will gain greater understanding of new developments such as eSie Touch elasticity 
and Virtual Tissue Imaging & Quantification (VTIQ, Siemens), both of which will 
be presented in this session. 
Ultrasound study of the pancreas with CPS (CEUS) and ARFI 
(elastography): improving the diagnosis of pancreatic tumours 
M. D’Onofrio; Verona/IT 
Image fusion enables us to perform a direct, on-screen correlation between a current 
ultrasound study and a previously performed CT or MRI exam. Using this ability, the 
spatial resolution of the ultrasound image can be added to the superior overview 
of a CT or MRI providing additional clinical confidence, lesions first noted on CT or 
MRI may be more easily detected and characterised on ultrasound and interven-
tions such as biopsies and tumour ablations may be guided by a combination of 
modalities. Participants in this symposium will become familiar with how image 
fusion adds another dimension both to diagnostic and interventional ultrasound. 
Image fusion: is this something we need? 
A. Nilsson; Uppsala/SE 
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12:30 - 13:30  Room F2 
organised by GE Healthcare
SY 13 
Developing innovative breast care solutions to 
improve clinical confidence 
Moderator: 
R.C. Sigal; Velizy/FR 
Case clarification with digital breast tomosynthesis versus 
mammography special views 
A. Stork; Düsseldorf/DE 
Purpose: Compare case clarification capability of Digital Breast Tomosynthesis 
(DBT) and Mammography Special Views (MSV) in a population of women with 
biopsied breast lesions.
Methods and Materials: 234 consenting women recalled for diagnostic work-up 
after inconclusive screening mammography and with indication of MSV, were 
proposed an additional DBT examination of the suspicious breast(s). DBT was 
performed with 15 exposures over an angle of 40° around the MLO position and a 
total dose equal to that of a 2-view standard mammography. MSV and DBT were 
read and scored on-line by an experienced breast radiologist.. Interpretations with 
BI-RADS scores ≥ 4a were considered positive. 59 of these women underwent 
biopsy of their suspicious lesions.
Results: Histology revealed 35 malignant and 24 benign cases. 64% and 71% of 
these cases were correctly classified by MSV and DBT, respectively. Amongst the 
malignant lesions, 3% and 26% were scored more accurately (equal or closer to 
BI-RADS 5) with MSV and DBT, respectively. In two patients, additional malignant 
lesions found with DBT were not detected on standard mammography and MSV.
Conclusions: Initial results show that DBT (MLO) may become a valuable replace-
ment of MSV in the diagnostic set-up. 
Contrast enhanced spectral mammography versus breast MRI - 
clinical experience 
E.M. Fallenberg; Berlin/DE 
Early detection of breast cancer through x-ray mammography (MX) has been shown 
to reduce mortality; however, the method is limited by a decreased sensitivity and 
specificity particularly in young patients and women with radiographically dense 
breasts, due to a reduced contrast difference between breast tumours and surround-
ing breast tissue. Furthermore, treatment options in breast cancer are depending on 
size of the lesions and additional foci. Therefore, independently of correct detection, 
accurate size estimation is mandatory to provide the best treatment option for every 
individual patient. To overcome the limitations of MX in staging, detection and size 
estimation in compromised conditions, MRI is a useful technique. However, only in 
a very limited number of cases breast MRI is performed due to high costs and low 
availability. The introduction of full field digital mammography gave the possibility to 
develop further technical methods, which are less expensive and widely available. 
One of these is contrast enhanced spectral mammography (CESM). CESM is able 
to increase sensitivity without decreasing specificity due to higher contrast and 
better lesion delineation than mammography alone. In this talk will be presented 
the background of CESM, how it is performed, clinical performance results versus 
mammography and ultrasound, as well as data comparing bilateral CESM, digital 
mammography and MRI on histologically proven breast cancers to postoperative 
histology results as gold standard. Potential advantages and disadvantages of 
CESM and MRI will be indicated and a sample of clinical cases will be presented 
to illustrate how CESM contributes to the detection of lesions and how it can be 
used in daily clinical workflow. 
New frontiers of advanced breast ultrasound 
A. Mundinger; Osnabrück/DE 
Advanced breast ultrasound (US) is going to expand its technological horizons 
that already include miniaturised and portable US systems, optimised 3- and 4-di-
mensional US, and hybrid systems combining different imaging modalities. The 
modern image presentation makes use of processing techniques known from MRI, 
helical CT and computerised image detection. The final aim of modern fusion and 
hybrid imaging is providing the image with the integrated quantitative information 
of distinct physical basic properties for every voxel within the three dimensional 
matrix of the breast volume to help the user improve tissue characterisation and 
detection of cancer. US reflection, interference, speed, attenuation, flow and 
elasticity coded imaging, X-ray attenuation and spectral information, magnetic 
diffusion and enhancement, receptor and metabolic activity and optical interfer-
Saturday, March 9
12:30 - 13:30  Room D1 
jointly organised by Siemens Healthcare  
and Bayer HealthCare
SY 10 
Synergies in CT for better patient care: cutting edge 
CT and optimised contrast media application 
Moderator: 
J.E. Wildberger; Maastricht/NL 
Clinical benefits of a new fully integrated CT detector
H. Alkadhi; Zurich/CH 
Optimise your CT results from scan to contrast media application
J.E. Wildberger; Maastricht/NL 
Protocol optimisation in cutting edge CT 
A.H. Mahnken; Marburg/DE 
12:30 - 13:30  Room E1 
organised by Bracco
SY 11 
Personalised CT imaging: a patient centric 
approach 
Moderator: 
M. Prokop; Nijmegen/NL 
Tailoring CT exams: when and how? 
C. Loewe; Vienna/AT 
How to balance radiation dose and diagnostic yield? 
H.-C. Becker; Munich/DE 
What if the patient is at risk? 
M.-F. Bellin; Le Kremlin-Bicêtre/FR 
12:30 - 13:30  Room E2
organised by Siemens Healthcare
SY 12 
Leading. With MAGNETOM. 
Moderator: 
T.J. Vogl; Frankfurt a. Main/DE 
Leading. With MAGNETOM.
N. Bolle; Erlangen/DE 
Novel imaging techniques in abdominal imaging
H.J. Michaely; Mannheim/DE 
Sustainability in a complex health care environment 
T.J. Vogl; Frankfurt a. Main/DE 
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ence are all candidates to make every voxel of the image more informative. The 
dream of tissue analysis goes on. Actual smaller steps in this direction have been 
implemented in updated high end US systems for better diagnosis using acoustic 
modelling based technology, elastography, fusion imaging of live US and MR 
volume data, or fusion of live US and plane mammography. Further options as 
3D imaging for lesion pattern study, or packages for lesions borders tracing may 
help in a comprehensive diagnosis leading to a suitable care path, as well as an 
improved workflow. Treatment planning is being complemented by elastography 
and fusion for pre-surgical assessment of lesion size, GPS to mark a lesion before 
biopsy, and 3D for anatomical volume overview. Advanced treatment guidance may 
involve also virtual tracking solutions for challenging biopsies. 
Role of MR DWI in breast cancer: correlation with histopathology 
V. Martinez de Vega; Madrid/ES 
12:30 - 13:30  Room G/H 
organised by Guerbet
SY 14 
Combining high tolerance with high diagnostic 
performance in contrast enhanced MRI 
Moderator: 
S.O. Schönberg; Mannheim/DE 
Introduction 
S.O. Schönberg; Mannheim/DE 
Tolerance of MR contrast agent in at risk patients 
G. Deray; Paris/FR 
The tolerance gadolinium chelates in healthy subjects have been uniformly favour-
able with no cases of Contrast induced nephropathy (CIN) or nephrogenic systemic 
fibrosis (NSF) reported, to our knowledge. gadolinium chelates appear to be safe 
and non nephrotoxic as intravenous CM in patients with normal renal function, 
as well as in patients with pre-existing RI, when used in doses similar to those 
recommended for MR imaging. In 2000, Cowper published the first report about 
a new scleromyxoedema in renal dialysis patents. Grobner then suggested a link 
between the development of similar skin lesions exposure to gadodiamide during. 
The new condition was named nephrogenic systemic fibrosis (NFS), because it 
was associated with fibrotic changes in many organs. Since then, approximately 
1,600 cases have been reported to the FDA. In 2007 the EMA stated that the use 
of gadodiamide and gadopentetare dimeglumine was contra-indicated in patients 
with GFR < 30 ml/min and in June 2007. Pro-FINEST prospectively determined 
the prevalence of NSF after a MRI examination, +/- GBCA, in dialysis patients. 571 
patients have been included: 50.3% received GBCA, 88.9% Gadoterate. No case 
of NSF has been reported in our 571 dialysis patients among whom the majority 
received a GBCA. When good clinical practices regarding the use of GBCA in a 
group at risk of NSF are followed, the NSF frequency is nil. Within patients who 
underwent an injected MRI 2.1% patients received linear GBCA but 93.4% received 
a macrolytic GBCA and 88. 9% received Gadoterate for which no unconfounded 
case of NSF has been observed yet worldwide. 
Optimal gadolinium concentration with high diagnostic accuracy 
M. Lell; Erlangen/DE 
Introduction: Peripheral arterial occlusive disease (PAOD) is a significant health 
problem in the western world. Non-invasive imaging is warranted to determine 
which patient profits from revascularisation. Contrast-enhanced MR angiography 
(CE-MRA) has evolved as the method of choice. To date, no large-scale prospective 
randomised trial comparing peripheral CE-MRA at 3T to the reference standard DSA 
has been performed. Therefore, the aim of this multicentre trial was to assess the 
diagnostic accuracy of CE- MRA at 3T compared to DSA and to demonstrate the 
clinical equivalence between the use of gadobutrol and Gd-DOTA. Methods: In this 
prospective, multi-country, multi-center, randomised, parallel group, double-blind, 
phase IV trial, 189 patients (66.4±10.7 years) with peripheral arterial disease (PAOD) 
(stages II-IV Leriche and Fontaine classification) were included. Patients randomly 
underwent MRA of the lower extremities during injection of 0.1mmol/kg Gd-based 
contrast agent (either Gd-DOTA (15.4±3.1mL) or gadobutrol (7.6±1.3mL)). A total 
of 21 vascular segments were assessed. Image assessment was performed 
on- and off-site. Agreement of CE- MRA with the reference standard DSA, using 
a non-inferiority analysis for the two different contrast agents, was evaluated in a 
blinded manner by on- and off- site reading. Sensitivity, specificity, positive, and 
negative predictive values (PPV, NPV) were calculated. Results: No statistically 
significant differences were found for both types of contrast agent in the detection 
of stenosis (Gd-DOTA, 80.6%±16.1%; gadobutrol, 77.1%±19.6%). The sensitivity 
for detecting significant stenosis (>50%) was 72.3% with Gd-DOTA and 70.6% with 
gadobutrol, the specificity (92.6% vs 92.3%), PPV (75.8% versus 72.7%), NPV 
(91.3% vs 91.5%), and diagnostic confidence (87.0% vs 86.0%).
Conclusion: Peripheral CE-MRA at 3T is feasible with high diagnostic accuracy. 
This study suggests that both contrast agents provide similar clinical information. 
MRI follow-up after kidney cancer cryoablation 
E. de Kerviler; Paris/FR 
The incidence of renal cell carcinoma (RCC) has been increasing in western 
countries in last 3 decades. More than two thirds of RCCs are found incidentally 
on a routine imaging workup. Also, more than 50% of patients are older than 65 
at diagnosis, some of them having serious comorbidities including impaired renal 
function. This has prompted to develop nephron sparing ablative therapies to treat 
RCCs percutaneously. These recent techniques, namely radiofrequency ablation 
and cryoablation need careful patients’ follow-up to assess successful procedure 
and to detect early recurrence. Whatever the imaging technique, the best indica-
tor for relapse is contrast enhancement. When compared with ultrasound and CT, 
MRI has multiplanar capabilities, is reproducible and has an excellent safety profile 
when a macrocyclic Gadolinium-based contrast agent such as Dotarem is used. 
Our follow-up protocol includes 7 CE-MRIs during the 2 years following ablation. 
Dotarem is usable even in patients with GRF below 30 ml/min, making it valuable 
for assessing treatment efficacy while avoiding serious adverse events such as NSF. 
Questions and conclusion
S.O. Schönberg; Mannheim/DE 
12:30 - 13:30  Room I/K 
organised by Philips Healthcare
SY 15 
Programme not available by date of print 
12:30 - 13:30  Room L/M 
organised by Philips Healthcare
SY 16 
News in mammography: spectral imaging in 
mammography screening
Moderator: 
M. Danielsson; Solna/SE 
Experiences of MicroDose in tailored breast cancer screening 
program including women between 40-49 years 
P. Panizza, A. Del Maschio; Milan/IT 
Latest development in mammography non-invasive single-shot 
spectral imaging 
S. Suryanarayanan; Andover, MA/US 
Spectral lesion evaluation: will it be possible to distinguish cysts 
from solid masses on the screening mammogram?
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Liver and pancreatic perfusion using Aquilion ONE vision 
J. Hermans; Nijmegen/NL 
Only few studies have been published about CT perfusion of the pancreas, partly 
due to the small volume of coverage with previous scanners. With the Aquilion ONE 
Vision (a rotation time of 0.275s) a volume with a coverage of 16 cm can be scanned, 
which makes it possible to scan the entire pancreas and a major part of the liver. 
During free breathing of the patient multiple sequential time points are acquired 
to obtain a tissue concentration curve. The time interval between acquisitions is 
small in the arterial phase (ca. 2s), is larger in the parenchynal phase (ca. 5s) and 
increases to 1 min in the late venous phase. However, until now there is no scan 
protocol that has been optimised for pancreas perfusion. This includes the volume 
and rate of contrast agent administration, kV and mAs, and the number of neces-
sary time points. The number of time points should be minimised as with perfusion 
CT the radiation dose is substantial. Because of movement of the pancreas in the 
z-axis during the acquisitions, the obtained high resolution perfusion images are 
registered in a non-rigid way, using one volume with maximal enhancement as a 
reference scan. Subsequently, perfusion maps can be calculated based on differ-
ent models. Quantitative analysis of tissue microcirculation can possibly be used 
for biological characterisation of solid pancreatic tumours and for evaluation of 
response to chemotherapeutic agents and-or radiotherapy. In the future perfusion 
parameters might be used to predict tumour aggressiveness and to design an 
individually tailored therapeutic approach. 
Learning Objectives:
1. To learn how to perform abdomen perfusion with volume CT, in particular liver 
and pancreas.
2. To learn how to optimize dose without compromising image quality in CT 
perfusion.
3. To understand the quantitative analysis of tissue microcirculation for evaluation 
of chemotherapeutic agents.
14:00 - 15:30  Room F2 
organised by Toshiba
SY 19 
Multimodal imaging for neuro applications 
Moderator: 
P.A. Brouwer; Leiden/NL 
Neuro applications using Aquilion ONE 
P.A. Brouwer; Leiden/NL 
The use of 320 row detector CT scanners in Neuroradiology opens a range of new 
possibilities. The 16 cm volume acquisition allows whole brain perfusion imaging in 
stroke patients, and the combination with subsecond temporal resolution enables 
4D- or time resolved CTA. The application of these techniques prove to be helpful 
in describing and understanding pathological processes but also in detection of 
specific neurovascular diseases. In this presentation the audience will become 
familiar with the properties of the CTA protocols used, and will learn about the 
neurovascular pathology, that can be depicted with these new techniques, through 
examplatory clinical cases. 
Learning Objectives:
1. To learn the clinical impact of CT with 16 cm coverage on neuro applications.
2. To understand pathological processes of neurovascular diseases.
3. To learn the properties of the CTA clinical protocols using 320-row CT.
Advanced neuroimaging at 3T with a 32ch head coil 
T. Okada; Kyoto/JP 
High density array coils with 3T imaging improve dramatically the available signal-
to-noise ratio (SNR), making a substantial reduction in scan time possible using 
parallel imaging to increase the spatial resolution of 2D and 3D acquisitions, al-
lowing sub-millimeter voxel sizes within clinically acceptable acquisition times. A 
wide range of brain imaging MR applications can be improved using a high SNR 
32 channel coil at 3T; with an in-plane resolution of 0.4 mm excellent details of the 
cortical and the deep gray matter structures can be captured. Using flow sensitive 
black blood (FSBB) imaging with an in plane resolution of 0.3mm, microvascula-
ture of the brain such as lenticulostriate arteries can be clearly visualised. With 
a parallel imaging factor of 4 a brain infarction protocol including a T2 weighted, 
a time-of-flight, a diffusion weighted and a perfusion weighted image could be 
scanned in 6 minutes or less. 
Learning Objectives:
1. To understand the added value of high density array coils at 3T.
14:00 - 15:30  Room C 
organised by Hologic
SY 17 
Celebrating the evolution of breast tomosynthesis: 
from research to large-scale, population-based 
screening programs, to advanced applications
Moderator: 
A. Smith; Bedford, MA/US 
A review of the evolution of breast tomosynthesis
A. Smith; Bedford, MA/US
The Oslo clinical tomosynthesis screening experience
P. Skaane; Oslo/NO 
Initial experience with tomosynthesis biopsy
D. Bernardi; Trento/IT
14:00 - 15:30  Room E1 
organised by Toshiba
SY 18 
Clinical advances in multimodality applications - 
new perspectives in perfusion and fusion imaging 
Moderator: 
B. Hamm; Berlin/DE 
The impact of smart fusion on the diagnostic outcome 
T. Fischer; Berlin/DE 
In recent years, advanced techniques have revolutionised ultrasound (US). The 
new possibilities comprise techniques for optimising image quality such as differ-
ential tissue harmonic imaging (THI) and frequency compounding (FC), tools for 
post-processing US raw data (ASQ and Precision Imaging) such as strain imaging 
(elastography), and the use of US contrast agents with new techniques (FlyThru; 
Image Fusion). The presentation will focus on characteristic features of abdominal 
organs, malignant liver lesions and prostate cancer detection using these state-of-
the-art UStechniques. For the improvement of the TRUS in the study presented 
here, we used ultrasound contrast agent imaging and compared it to magnetic 
resonance imaging (MRI), Elastography, Image Fusion (ultrasound plus MRI) and 
histology after biopsy. 
Learning Objectives:
1. Puncture and postoperative quality control using new US techniques.
2. Detection of focal liver lesions and monitoring of therapy for liver metastases 
using Image Fusion.
3. Presentation of examples to work out the benefits of Image Fusion in the field 
of prostate cancer detection and TRUS biopsy.
CEUS of the kidney: from new technology to patient management 
improvement 
J.-M. Correas; Paris/FR 
Contrast-Enhanced Ultrasound (CEUS) indications can be extended to renal dis-
eases. New sequences have become available on several transducers including 
convex and linear probes and improve the sensitivity and resolution of the contrast 
modes. Together with Tissue Harmonic Imaging, the diagnostic performance of US 
has been improved particularly for the detection of small renal masses and the 
characterisation of peripheral vascular disorders and atypical cystic masses. The 
percutaneous conservative management of renal masses beneficiate from both 
image quality and fusion imaging for guiding electrode placement and evaluating 
therapeutic efficacy. Applications such as 4D CEUS and quantitative assessment 
of perfusion should leave the research teams and become part of the clinical 
applications. 
Learning Objectives:
1. To become familiar with new CEUS applications and settings.
2. To understand the classification of peripheral vascular disorders and atypical 
cystic renal masses.
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2. To learn how to take advantage of the increased SNR at 3T to improve spatial 
and temporal resolution in advance brain imaging.
3. To apply new scanning parameters in fast routine brain imaging .
Neurological interventions using Toshiba Infinix 
H. Fransen; Gent/BE 
In recent years, advanced techniques have been introduced in angiography 
(XR). The new possibilities comprise techniques for optimising image quality dur-
ing interventional procedures in neurology and the introduction of new imaging 
techniques like Volume Navigation - 3D Road Mapping, Needle Guidance, Low 
Contrast Imaging and Multimodality imaging. The presentation will focus on com-
plex aneurysm interventions. The advanced angiography equipment we have at 
our department allows us to see the blood vessel, the aneurysm or AVM , and the 
microcatheter all together continuously from the front and the side. Together with 
the 3D roadmapping and the CT multimodality it gives you during the embolisation 
a higher sense of security and precision. 
Learning Objectives:
1. Visualisation of aneurysm or AVM.
2. Use of advanced techniques like Volume Navigation - 3D Road Mapping, 
Needle Guidance, Low Contrast Imaging and Multimodality imaging.
3. Presentation of examples to work out the benefits of new imaging techniques 
related to the interventional procedure in aneurysm or AVM treatment.
14:00 - 15:30  Room L/M 
organised by GE Healthcare Nycomed
SY 20 
CT and MR diagnostic capabilities and safety: new 
tendency 
Moderators: 
V.N. Kornienko; Moscow/RU  
I.E. Tyurin; Moscow/RU 
Low-dose and low-iodine CT coronary angiography 
V.E. Sinitsyn; Moscow/RU 
CTA has been widely used for coronary imaging. But still further decreases of 
radiation exposure and volume of contrast media (CM) are desirable. Results of 
latest studies have been shown that low-dose coronary CTA could be performed 
in combination with low iodine load. Total dose of iodine could be decreased up 
to about 25%. There is possibility to use CM with concentration 270-300 mgI/ml 
instead of 320-350 mgI/ml. Decrease in tube kV is associated with higher values 
of measured Hounsfield units and corresponding increase of image noise. Use of 
iterative reconstruction technique (ASiR) for coronary CTA results in low image 
noise. Prospective gating and low tube kV decrease radiation exposure to patient 
(<2-3 mSv). Low-dose, low-iodine coronary CTA performed with systems having 
options of high-definition imaging, prospective gating and interative image recon-
struction may change current approach to diagnostic work-up of coronary patients. 
MRI safety - actual issues 
E.A. Mershina; Moscow/RU 
Magnetic resonance imaging (MRI) has become an important tool for diagnosis and 
treatment control of many diseases. Patients with cardiac implantable electronic 
devices such as permanent pacemakers and implantable defibrillators are usually 
excluded from MRI examinations since the majority of implantable devices have a 
contraindication for MRI. The probability to have indications for MRI are doubled 
after age of 65 years, 17% of patients will need MRI in 1 year after permanent 
pacemaker implantation. As a result of patients’ needs (and their physicians’) dif-
ferent manufacturers recently released permanent implantable pacemaker systems 
which are designed with respect to the potential adverse effects of MR on permanent 
pacemakers. Main risks for patients with implanted pacemakers and different ways 
to change the construction of pacemakers to make them MRI-compatible will be 
discussed. The results of trials and our own results will be demonstrated. 
Brain - heart - axis 
R. Rienmüller; Graz/AT 
The continuous technologic improvement of cardiac CT and MR enables to measure 
myocardial perfusion in absolute numbers (ml/100g/min) on a daily routine basis. 
This important functional parameter of the heart, however is not only dependant on 
the state of the morphology of the coronary vessel wall but also on number of direct 
and derived determinants of myocardial perfusion. These are under the superior 
control of the neuro-vegetative system. The regulation of myocardial perfusion 
appears as a very complex process, where the neuro-vegetative system plays an 
important role as superior controlling mechanism. The goal of the presentation 
is 1) to review the essential anatomic structures of the brain and of the nervous 
connecting system which interfere with and control the individual cardiac function. 
2) to describe neuro-humoral regulations which serve as protective mechanism to 
prevent or at least to reduce the extent of myocardial ischemia. 
Russian radiology best practice - clinical experience sharing 
A. Lukianchenko; Moscow/RU 
GE Healthcare innovative solutions for modern healthcare 
V.I. Grischenko; Moscow/RU 
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Clinical and cost effectiveness of CEUS for liver imaging: the NICE 
diagnostics guidance 
T. Hoare; Newcastle Upon Tyne/UK Sunday, March 10
12:30 - 13:30  Room C 
organised by GE Healthcare
SY 21 
Patient care and image quality: at the forefront of CT 
innovations and contrast media 
Moderator: 
V.E. Sinitsyn; Moscow/RU 
Iodinated contrast media in CT: defining the key properties 
Optimising image quality and patient care in cardiac CT 
D. Andreini; Milan/IT 
Spectral imaging: clinical breakthrough in oncology 
P. Ardies; Malle/BE 
Many promising clinical applications have been reported for Spectral Imaging 
Computed Tomography (CT) in Oncology Imaging in the last years. Several studies 
have shown the unique capabilities Spectral Imaging CT provides for characterising 
hypervascular liver lesions by increasing the iodine conspicuity thanks to low keV 
monochromatic images reconstructions. Moreover, Spectral Imaging CT has also 
been shown to enable accurate iodine quantification, therefore allowing for a more 
precise kidney lesions characterisation. Virtual unenhanced images reconstructed 
from Spectral Imaging CT datasets can be useful for differentiating hemorrhagic 
cysts from enhancing lesions, potentially reducing the need for an unenhanced 
scanning phase. Although this acquisition mode had some limitations in the past, 
mainly linked to a significant increase in radiation dose, the latest advances in 
scanning protocols and radiation dose reduction technologies have enabled to 
use Spectral Imaging CT with no dose penalty for the patient. The aim of this 
presentation is to discuss about the unique clinical benefits that Spectral Imaging 
CT can provide in oncology imaging and highlight the most promising clinical ap-
plications in this field. 
12:30 - 13:30  Room G/H 
organised by Samsung
SY 22 
Programme not available by date of print 
12:30 - 13:30  Room L/M 
organised by Philips Healthcare
SY 23 
Programme not available by date of print 
12:30 - 13:30  Room N/O 
organised by Bracco
SY 24 
Cost-effectiveness and improvement of patient 
management with contrast enhanced ultrasound 
(CEUS) 
Moderator: 
G.H. Mostbeck; Vienna/AT 
Implementation of CEUS in the daily practice of the imaging center 
M. Wüstner; Trier/DE 
CEUS in interventional radiology: clinical outcomes and impact on 
patient management 
E.M. Jung; Regensburg/DE 
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